Quantum-Si Announces Presentations at ASMS and ESHG
31 Maggio 2024 - 2:00PM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
presentations at two upcoming industry conferences. Gloria
Sheynkman, PhD, Assistant Professor in the Department of Molecular
Physiology and Biological Physics at the University of Virginia’s
lab will present a poster developed in collaboration with
Quantum-Si at the American Society for Mass Spectrometry (ASMS)
annual meeting being held June 2-6, 2024. Dr. Brian Reed, Head of
Research at Quantum-Si will present at the European Society for
Human Genetics (ESHG) annual meeting being held June 1-4, 2024.
Results of the study to be presented, by Natchanon
Sittipongpittaya from Dr. Sheynkman’s lab at ASMS, represent the
first integration of single-molecule detection methods with
proteogenomics to detect proteotypic and isoform-selective
peptides.
Long read transcriptomics (LR-RNA-seq) revealed multiple
annotated and novel isoforms (i.e., spliceforms) of vimentin, TPM1
and TPM2. Like many alternatively spliced isoforms, much of the
predicted protein sequences are highly overlapping and difficult to
distinguish. Additionally, TPM1 and TPM2, being closely related
paralogs, also have high sequence identity (87%). Using the
Platinum platform, protein sequencing distinguished
isoform-specific peptides for filament proteins involved in cancer
and skeletal muscle diseases.
At ESHG, Dr. Reed will discuss the expanding role of
Next-Generation Protein Sequencing™ (NGPS) in advancing biological
research by enabling any researcher to sequence proteins in their
lab. Quantum-Si’s protein sequencer, Platinum®, is a compact and
affordable benchtop device that enables direct sequencing of
proteins with single-amino-acid resolution using a simple workflow.
NGPS is a transformative technology that enables direct
interrogation of protein primary structure, post-translational
modifications (PTMs), and protein isoform diversity.
Presentation details are as follows:
ASMS
Title: Integrated sequencing of transcripts and proteins
at the single molecule level to detect isoforms and proteolytic
peptides in filament biomarkers
Session: Proteomics: New Approaches
Authors: Gloria Shenykman, PhD and Natchanon
Sittipongpittaya, both of the University of Virginia and Kenneth
Skinner, PhD, Quantum-Si
Date and Time: June 3, 10:30 am - 12:30 pm and 1:30 -
2:30 pm PDT
ESHG
Title: Beyond the Genome: Unlocking Proteomic Discoveries
with Quantum-Si’s Next-Generation Protein Sequencing™
Technology
Presenter: Brian Reed, PhD
Date and Time: Sunday, June 2, 8:30 -10:00 a.m. BST
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company’s
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at quantum-si.com or
follow us on LinkedIn or X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240531086657/en/
Investor Contact Jeff Keyes, Chief Financial Officer
ir@quantum-si.com Media Contact Katherine Atkinson, SVP,
Commercial Marketing media@quantum-si.com
Grafico Azioni Quantum Si (NASDAQ:QSI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Quantum Si (NASDAQ:QSI)
Storico
Da Set 2023 a Set 2024